211 related articles for article (PubMed ID: 38020763)
1. The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer's disease: a meta-analysis.
Li J; Wu X; Tan X; Wang S; Qu R; Wu X; Chen Z; Wang Z; Chen G
Front Aging Neurosci; 2023; 15():1257973. PubMed ID: 38020763
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Qiao Y; Gu J; Yu M; Chi Y; Ma Y
CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.
Wang XC; Chu CL; Li HC; Lu K; Liu CJ; Cai YF; Quan SJ; Zhang SJ
Front Neurol; 2022; 13():1018027. PubMed ID: 36530613
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
Jeremic D; Navarro-López JD; Jiménez-Díaz L
Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
[TBL] [Abstract][Full Text] [Related]
6. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey RJ
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
[TBL] [Abstract][Full Text] [Related]
7. Effects of three kinds of anti-amyloid-β drugs on clinical, biomarker, neuroimaging outcomes and safety indexes: A systematic review and meta-analysis of phase II/III clinical trials in Alzheimer's disease.
Lyu D; Lyu X; Huang L; Fang B
Ageing Res Rev; 2023 Jul; 88():101959. PubMed ID: 37217078
[TBL] [Abstract][Full Text] [Related]
8. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
Wessels AM; Dowsett SA; Sims JR
J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Agents Targeting γ-Secretase Increase Risk of Cancer and Cognitive Decline in Alzheimer's Disease Patients: A Systematic Review and Meta-Analysis.
Penninkilampi R; Brothers HM; Eslick GD
J Alzheimers Dis; 2016 Jul; 53(4):1395-404. PubMed ID: 27392862
[TBL] [Abstract][Full Text] [Related]
10. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
Qiao Y; Chi Y; Zhang Q; Ma Y
Front Aging Neurosci; 2023; 15():1169499. PubMed ID: 37213538
[TBL] [Abstract][Full Text] [Related]
12. Lecanemab in Early Alzheimer's Disease.
van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
[TBL] [Abstract][Full Text] [Related]
13. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
Avgerinos KI; Ferrucci L; Kapogiannis D
Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
[TBL] [Abstract][Full Text] [Related]
14. Minimal clinically important difference in Alzheimer's disease: Rapid review.
Muir RT; Hill MD; Black SE; Smith EE
Alzheimers Dement; 2024 May; 20(5):3352-3363. PubMed ID: 38561021
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of monoclonal antibodies against amyloid-beta
Hao Y; Dong M; Sun Y; Duan X; Niu W
Front Neurol; 2023; 14():1147757. PubMed ID: 37006475
[TBL] [Abstract][Full Text] [Related]
16. Effects of rTMS treatment on global cognitive function in Alzheimer's disease: A systematic review and meta-analysis.
Zhang T; Sui Y; Lu Q; Xu X; Zhu Y; Dai W; Shen Y; Wang T
Front Aging Neurosci; 2022; 14():984708. PubMed ID: 36158564
[TBL] [Abstract][Full Text] [Related]
17.
Zhang Y; Tian J; Ni J; Wei M; Li T; Shi J
Front Pharmacol; 2023; 14():1268000. PubMed ID: 38283842
[No Abstract] [Full Text] [Related]
18. The efficacy of statins in the treatment of Alzheimer's disease: a meta-analysis of randomized controlled trial.
Xuan K; Zhao T; Qu G; Liu H; Chen X; Sun Y
Neurol Sci; 2020 Jun; 41(6):1391-1404. PubMed ID: 31930449
[TBL] [Abstract][Full Text] [Related]
19. Memantine for dementia.
McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
Monteiro C; Toth B; Brunstein F; Bobbala A; Datta S; Ceniceros R; Sanabria Bohorquez SM; Anania VG; Wildsmith KR; Schauer SP; Lee J; Dolton MJ; Ramakrishnan V; Abramzon D; Teng E;
Neurology; 2023 Oct; 101(14):e1391-e1401. PubMed ID: 37643887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
